J. Goldman & Co LP Invests $1.15 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

J. Goldman & Co LP purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 26,335 shares of the company's stock, valued at approximately $1,152,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RVMD. Boxer Capital Management LLC acquired a new position in Revolution Medicines during the fourth quarter valued at approximately $187,184,000. Janus Henderson Group PLC lifted its holdings in shares of Revolution Medicines by 54.5% during the 4th quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock valued at $414,777,000 after acquiring an additional 3,346,755 shares in the last quarter. Vanguard Group Inc. lifted its position in Revolution Medicines by 14.7% during the 4th quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company's stock worth $747,799,000 after acquiring an additional 2,185,082 shares in the last quarter. Farallon Capital Management LLC grew its holdings in Revolution Medicines by 17.1% during the 4th quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock valued at $579,498,000 after purchasing an additional 1,931,000 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Revolution Medicines during the fourth quarter worth about $76,197,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD traded down $0.04 during midday trading on Thursday, reaching $39.44. 899,044 shares of the company traded hands, compared to its average volume of 1,491,953. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $62.40. The stock has a 50-day moving average price of $37.42 and a 200 day moving average price of $43.31. The company has a market cap of $7.35 billion, a price-to-earnings ratio of -10.99 and a beta of 1.11.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same period in the prior year, the business earned ($0.70) EPS. As a group, analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on RVMD shares. Guggenheim cut their price target on shares of Revolution Medicines from $87.00 to $80.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Stifel Nicolaus reduced their price objective on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Wedbush reaffirmed an "outperform" rating and issued a $67.00 target price on shares of Revolution Medicines in a research report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and set a $72.00 price target (down previously from $73.00) on shares of Revolution Medicines in a report on Wednesday. Finally, Oppenheimer upped their price target on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $67.08.

Insider Buying and Selling

In other Revolution Medicines news, insider Mark A. Goldsmith sold 11,738 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $458,251.52. Following the completion of the sale, the insider now directly owns 441,564 shares of the company's stock, valued at approximately $17,238,658.56. This represents a 2.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Margaret A. Horn sold 3,058 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $119,384.32. Following the completion of the transaction, the chief operating officer now directly owns 153,533 shares in the company, valued at $5,993,928.32. This represents a 1.95% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,660 shares of company stock valued at $650,406 over the last quarter. Corporate insiders own 8.20% of the company's stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.